Management of adverse events associated with idelalisib treatment: expert panel opinion

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing informati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4732460/
https://ncbi.nlm.nih.gov/pubmed/25726955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1022770
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados